View Older Stories View More Recent Stories

May 10, 2023 07:32AM G1 Therapeutics (GTHX) Reports New Results from Phase 2 Trial Confirm Benefit of Trilaciclib
May 10, 2023 07:31AM New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
May 3, 2023 06:30AM G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
May 1, 2023 05:00PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 26, 2023 12:45PM G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
Apr 11, 2023 12:30PM G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
Mar 1, 2023 06:30AM G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Mar 1, 2023 06:30AM G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Feb 28, 2023 02:10PM G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
Feb 22, 2023 10:00AM G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023
Feb 13, 2023 06:01AM G1 Therapeutics (GTHX) Reports Top Line Results from Phase 3 Trial of Trilaciclib
Feb 13, 2023 06:00AM G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE
Feb 9, 2023 08:00AM First Prescription for COSELA® (trilaciclib) Issued in China
Feb 1, 2023 04:46PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 11, 2023 07:00AM G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference
Jan 9, 2023 06:31AM G1 Therapeutics (GTHX) Announces Upcoming 2023 Readouts from Phase 2 and Phase 3 Trials of Trilaciclib
Jan 9, 2023 06:30AM G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
Jan 4, 2023 06:31AM G1 Therapeutics (GTHX) provides initial update on PRESERVE 3
Jan 4, 2023 06:30AM G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023
Jan 3, 2023 02:00PM G1 Therapeutics to Participate in the 41st Annual J.P. Morgan Conference
Dec 7, 2022 06:04PM Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment
Dec 1, 2022 11:41PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 23, 2022 10:30AM G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference
Nov 2, 2022 06:30AM G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
Nov 2, 2022 06:30AM G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
Nov 2, 2022 06:29AM G1 Therapeutics (GTHX) Reports Strong Phase 2 Results of Trilaciclib
Nov 2, 2022 06:28AM Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)
Nov 1, 2022 05:40PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 26, 2022 09:27AM G1 Therapeutics (GTHX) Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin
Oct 26, 2022 09:26AM G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Oct 19, 2022 12:30PM G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022
Oct 10, 2022 06:30AM G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)
Oct 3, 2022 05:00PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 7, 2022 08:00AM G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference
Sep 6, 2022 07:00AM G1 Therapeutics to Host Virtual R&D Day on September 15, 2022
Sep 1, 2022 05:22PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 3, 2022 06:30AM G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights
Aug 1, 2022 05:15PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 1, 2022 09:00AM G1 Therapeutics to Participate Virtually in the 2022 BTIG Biotechnology Conference and the 2022 Wedbush Pacgrow Healthcare Conference
Jul 25, 2022 06:31AM G1 Therapeutics (GTHX) Appoints Norman E. Sharpless to its Board
Jul 25, 2022 06:30AM G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors
Jul 20, 2022 09:00AM G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022
Jul 13, 2022 10:16AM G1 Therapeutics (GTHX) Announces COSELA Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
Jul 13, 2022 10:15AM COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-
Jul 13, 2022 10:15AM COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-
Jul 1, 2022 05:20PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 28, 2022 07:32AM G1 Therapeutics (GTHX) Appoints Jacks Lee to its Board
Jun 28, 2022 07:30AM G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors
Jun 13, 2022 07:00AM G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer
Jun 2, 2022 11:00AM Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Pati
View More Recent Stories View Older Stories